On the road to better dyslipidemia outcomes.
Hughes
Suzanne
S
Robinson Memorial Hospital, Ravenna, Ohio, USA.
D001384:Azetidines / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002995:Clofibric Acid / Q000627:therapeutic use; D050171:Dyslipidemias / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D000069438:Ezetimibe; D005395:Fish Oils / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style; D050356:Lipid Metabolism; D024821:Metabolic Syndrome / Q000175:diagnosis; D009525:Niacin / Q000627:therapeutic use; D010808:Physical Examination; D018570:Risk Assessment; D012307:Risk Factors; D014803:Vitamin B Complex / Q000627:therapeutic use
D001384:Azetidines; D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014803:Vitamin B Complex; D009525:Niacin; D002995:Clofibric Acid; D000069438:Ezetimibe